×
About 210 results

ALLMedicine™ Primary Pulmonary Hypertension Center

Research & Reviews  69 results

Diagnosis and management of congenital umbilical arteriovenous malformation.
https://doi.org/10.1017/S1047951120004138
Cardiology in the Young; Bakhru S, Jamalpuri V et. al.

Dec 3rd, 2020 - An 8-day-old neonate was presented with severe respiratory distress and diagnosed as primary pulmonary hypertension of the newborn on functional echocardiogram. Evaluation showed bounding pulse, enlarged umbilical cord, and bruit over the periumbi...

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS OF MICROVASCULAR AND NEURAL CHANGES I...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989611
Retina (Philadelphia, Pa.); Gu S, Li Z et. al.

Aug 11th, 2020 - To investigate the microvascular and neural changes in primary pulmonary hypertension (PPH) patients compared with healthy controls. Forty-four eyes of 22 PPH patients were included in this observational clinical cohort study, and 44 eyes of 22 he...

Single Lung Transplant vs Double Lung Transplant: A Single-Center Experience With Parti...
https://doi.org/10.1016/j.transproceed.2020.03.046
Transplantation Proceedings; Antończyk R, Stącel T et. al.

Jun 1st, 2020 - Lung transplant remains the only viable treatment for certain patients with end-stage lung diseases. Such patients can become either single or double lung recipients. The 2 procedures are associated with specific risks and benefits. The aim of the...

Extracorporeal Membrane Oxygenation as a Postoperative Left Ventricle Conditioning Tool...
https://doi.org/10.1016/j.transproceed.2020.02.113
Transplantation Proceedings; Stącel T, Antończyk R et. al.

Apr 7th, 2020 - Primary pulmonary hypertension can lead to hypertrophy of the right ventricle and ultimately to its insufficiency. Lung transplantation remains the only viable treatment for patients with certain forms of this disease. Usage of extracorporeal memb...

Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lun...
https://doi.org/10.1016/j.healun.2020.01.475
The Journal of Heart and Lung Transplantation : the Offic... Vos R, Smits JM et. al.

Mar 30th, 2020 - Following introduction of the lung allocation score (LAS) in 2011, Eurotransplant member centers can apply for an exceptional LAS (eLAS) if the calculated LAS insufficiently reflects the perceived transplant benefit for a patient, specifically in ...

see more →

Drugs  4 results see all →

News  9 results

Avenues for protecting against vasculopathy in systemic sclerosis
https://www.mdedge.com/dermatology/article/82448/lupus-connective-tissue-diseases/avenues-protecting-against-vasculopathy/page/0/1

May 19th, 2014 - Endothelin inhibitors Endothelin inhibitors also may play a role in vascular protection. Endothelin is secreted in scleroderma and is a potent vasoconstrictor.

RVH or Posterior MI? Make the Diagnosis
https://www.medscape.com/viewarticle/762321_2

Apr 20th, 2012 - Answer Right ventricular hypertrophy Discussion In this tracing, QRS axis tends to the right axis deviation (RAD), which should make one think of right ventricular hypertrophy (RVH) first. After the RAD, all other diagnostic features of RVH are fo...

MRI Identifies Metabolic Abnormalities in Brain After ECMO
https://www.medscape.com/viewarticle/754137

Nov 28th, 2011 - November 28, 2011 (Chicago, Illinois) — Approximately half of the neonates who receive extracorporeal membrane oxygenation (ECMO) have cerebral atrophy. Magnetic resonance imaging (MRI) has shown that the N-acetylaspartate/creatine (NAA/Cr) ratio ...

Endobronchial Dysplasia Could Be Marker for Lung Cancer Chemoprevention
https://www.mdedge.com/content/endobronchial-dysplasia-could-be-marker-lung-cancer-chemoprevention-1
Sharon Worcester

Apr 6th, 2011 - ORLANDO – Endobronchial dysplasia appears useful as a biomarker for measuring the success of lung cancer chemoprevention, investigators reported at the annual meeting of the American Association for Cancer Research. Bronchoscopies, along with biop.

Pfizer Pulls PAH Drug Due to Liver Toxicity
https://www.medscape.com/viewarticle/734024

Dec 10th, 2010 - December 10, 2010 (New York, New York) — Pfizer is to voluntarily withdraw sitaxentan (Thelin), a drug for pulmonary arterial hypertension (PAH), following two cases of fatal liver toxicity [1]. The drug has been marketed in 16 countries in the Eu...

see more →

Patient Education  2 results see all →